Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Randomized, Double-blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

NCT06063330 is registered in ClinicalTrials.gov with Red Queen Therapeutics, Inc. as lead sponsor.

NCT NCT06063330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06063330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Randomized, Double-blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
Lead sponsor
Red Queen Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2023
Completion date
January 3, 2024
Enrollment
66 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, infectious disease, sars cov 2 infection, symptomatic covid-19 infection laboratory-confirmed